Fulminant hepatic failure secondary to erlotinib

被引：36

作者：

Liu, Weitian ^{[1
]}

Makrauer, Frederick L.

Qamar, Amir A.

Jaenne, Pasi A.

Odze, Robert D.

机构：

[1] Harvard Univ, Sch Med, Div Gastroenterol Hepatol & Endoscopy, Brigham & Womens Hosp, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Hosp Canc Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2007年 / 5卷 / 08期

关键词：

D O I：

10.1016/j.cgh.2007.04.014

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Erlotinib is a tyrosine kinase inhibitor recently approved by the Food and Drug Administration for the treatment of non-small-cell lung cancer and pancreatic cancer. We report a case of a patient with stage IV non-small-cell lung cancer who died of fulminant hepatic failure as a result of treatment with erlotinib.

引用

页码：917 / 920

页数：4

共 24 条

[1] Dermatologic side effects associated with the epidermal growth factor receptor inhibitors [J].

Agero, Anna Liza C. ;

Dusza, Stephen W. ;

Benvenuto-Andrade, Cristiane ;

Busam, Klaus J. ;

Myskowski, Patricia ;

Halpern, Allan C. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) :657-670

[2] FDA drug approval summary:: Gefitinib (ZD1839) (Iressa®) tablets [J].

Cohen, MH ;

Williams, GA ;

Sridhara, R ;

Chen, G ;

Pazdur, R .

ONCOLOGIST, 2003, 8 (04) :303-306

[3] INHIBITION OF MITOCHONDRIAL BETA-OXIDATION AS A MECHANISM OF HEPATOTOXICITY [J].

FROMENTY, B ;

PESSAYRE, D .

PHARMACOLOGY & THERAPEUTICS, 1995, 67 (01) :101-154

[4] Erlotinib: Optimizing therapy with predictors of response? [J].

Goodin, Susan .

CLINICAL CANCER RESEARCH, 2006, 12 (10) :2961-2963

[5] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

[6] Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [J].

Hidalgo, M ;

Siu, LL ;

Nemunaitis, J ;

Rizzo, J ;

Hammond, LA ;

Takimoto, C ;

Eckhardt, SG ;

Tolcher, A ;

Britten, CD ;

Denis, L ;

Ferrante, K ;

Von Hoff, DD ;

Silberman, S ;

Rowinsky, EK .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3267-3279

[7] Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of erlotinib (Tarceva) [J].

Hidalgo, M ;

Bloedow, D .

SEMINARS IN ONCOLOGY, 2003, 30 (03) :25-33

[8] Side effects related to cancer treatment - Case 1. Hepatitis following treatment with gefitinib [J].

Ho, C ;

Davis, J ;

Anderson, F ;

Bebb, G ;

Murray, N .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8531-8533

[9] Forum - Mechanisms of hepatotoxicity [J].

Jaeschke, H ;

Gores, GJ ;

Cederbaum, AI ;

Hinson, JA ;

Pessayre, D ;

Lemasters, JJ .

TOXICOLOGICAL SCIENCES, 2002, 65 (02) :166-176

[10] Drug-induced liver injury [J].

Kaplowitz, N .

CLINICAL INFECTIOUS DISEASES, 2004, 38 :S44-S48

← 1 2 3 →